Early tranexamic acid (TXA) administration following an injury has decreased mortality rates in both military and civilian populations.1,2 Consequently, TXA is now incorporated as an adjunct to blood product–based “damage control resuscitation” protocols in not only civilian trauma centers, but also in deployed combat casualty care in which the early adoption of TXA was driven by limitations of blood component availability in austere settings.3-7